Detalhe da pesquisa
1.
Lung Injury Prediction Model in Bone Marrow Transplantation: A Multicenter Cohort Study.
Am J Respir Crit Care Med
; 209(5): 543-552, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38051944
2.
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
Br J Haematol
; 204(1): 171-176, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37710381
3.
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Br J Haematol
; 204(4): 1232-1237, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311378
4.
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.
Haematologica
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546692
5.
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299584
6.
Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
Eur J Haematol
; 112(1): 51-63, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38105391
7.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Am J Hematol
; 99(2): 193-202, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071734
8.
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Am J Hematol
; 99(2): E63-E66, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100217
9.
The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
Br J Haematol
; 202(2): 279-283, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37144345
10.
Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms.
Haematologica
; 108(11): 3033-3043, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199125
11.
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
Am J Hematol
; 98(3): 472-480, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36625066
12.
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
Br J Haematol
; 196(4): 963-968, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34697797
13.
Membranous Nephropathy With Extensive Tubular Basement Membrane Deposits Following Allogeneic Hematopoietic Cell Transplant: A Report of 5 Cases.
Am J Kidney Dis
; 79(6): 904-908, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34508832
14.
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
Am J Hematol
; 97(8): 1013-1022, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35560061
15.
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
Am J Hematol
; 97(9): 1127-1134, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35702875
16.
Use of sublingual tacrolimus in adults undergoing hematopoietic cell transplant: A pilot study.
J Oncol Pharm Pract
; 28(2): 387-394, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33593135
17.
Pilot Study Characterizing the Hematology-Oncology Fellow Job Search Process: Tools Used and Identification of Potential New Resources.
J Cancer Educ
; 37(5): 1385-1388, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33517561
18.
Chronic graft-versus-host disease in pancreas after kidney transplant recipients - An unrecognized entity.
Am J Transplant
; 21(2): 883-888, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32805087
19.
Immune-mediated neuromuscular complications of graft-versus-host disease.
Muscle Nerve
; 63(6): 852-860, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33651380
20.
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Am J Hematol
; 96(7): 781-789, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844862